Not Just Another Index.
It’s The New Generation.®
We offer specialized solutions for investors seeking exposure to New Listings - a proxy for economic growth and innovation.
New: The IPOX® High Dividend 7% Strategy
An Innovative Index Strategy
combining Income & Growth!
Upcoming Global IPOs
The IPOX® Newsletters
IPO News
The IPO market is showing strong signs of a rebound in mid-2025, fueled by improving economic stability and renewed investor confidence. After a period of caution, a solid pipeline of companies, particularly in the technology and life sciences sectors, is now emerging. High-profile debuts have performed well, encouraging other unicorns to accelerate their listing plans. While market volatility remains a consideration, the overall sentiment is optimistic for a more active and receptive second half.
Global IPO markets are active, with strong showings in the Middle East as Saudi airline flynas and healthcare firm SMC launch successful offerings. The Asia-Pacific region is also bustling with major listings in the Philippines and Australia, while Hong Kong's market rebounds. In contrast, London faces setbacks as fintech Wise shifts its primary listing to the U.S. and Cobalt Holdings cancels its float, even as U.S. crypto and aerospace firms successfully go public.
Global IPO activity remains dynamic. The U.S. sees Netskope targeting a $5B+ IPO valuation and Omada Health raising $158M. Europe anticipates a potential £4.5B Automobile Association deal and Cobalt Holdings' $230M IPO. In Asia-Pacific, Shein considers a Hong Kong listing, Sony plans a major financial arm spin-off, and 'Baby Shark' creator Pinkfong files its IPO, showcasing diverse market movements across key financial hubs.
IPOX® in the News
In a Reuters article covering Chime’s IPO, IPOX® VP Kat Liu, provided expert commentary on the implications of the company’s strong market reception. Ms. Liu noted that the performance of a high-profile "unicorn" like Chime is being closely watched and could encourage other private fintech companies to move forward with their own public offerings.
In a Reuters article covering the successful market debut of Voyager Technologies, IPOX® Associate Lukas Muehlbauer was quoted in the piece, stating, "Strategic government backing amid increased defense spending somewhat shields these [defense] firms from tariff-induced supply chain risks." His analysis underscores the unique factors contributing to the resilience and attractiveness of companies within the sector.
In a recent Bloomberg article, IPOX® Founder Josef Schuster provided his expert commentary on the U.S. IPO market's recent surge in performance. He described a "positive feedback loop" where unsatisfied demand for one hot listing is driving investor orders for the next, contributing to the market's momentum. Schuster noted that while this enthusiasm is promising, the true test for the recovery will be the fundamental strength shown in the first quarterly earnings from these newly public companies, stating, "When you see the first set of earnings from some of these companies, you will really see how substantial this recovery of the IPO market is going to be."
In a recent Reuters article, IPOX® VP Kat Liu, provided commentary on the upcoming IPO of property insurance technology company Slide. The company is reportedly targeting a valuation of up to $2.12 billion and aims to raise as much as $340 million.
In a recent report by Reuters, IPOX® Research Associate Dr. Lukas Muehlbauer provided commentary on the upcoming U.S. initial public offering of cancer diagnostic firm Caris Life Sciences. The company is aiming for a valuation of up to $5.3 billion, seeking to raise as much as $423.5 million.